Dose-range finding (DRF) and maximum tolerated dose (MTD) studies are necessary for de-risking the clinical translation of novel biologic scaffolds. These non-GxP investigations establish the initial safety profile, define the therapeutic window, and inform dose selection for subsequent GxP toxicology programs. A well-designed MTD study for complex biologics, such as gene therapy vectors, requires a nuanced approach that accounts for potential on-target, off-tissue toxicities and complex biodistribution patterns. This asset outlines the strategic design and execution of these studies, ensuring a robust data package for IND submission.

Frequently Asked Questions: DRF & MTD Study Design

Defining the Therapeutic Window for Complex Biologics

Establishing a safe and effective starting dose for a first-in-human trial begins with a robust non-clinical toxicology program. For novel biologic scaffolds, particularly vectors used in gene therapy, dose-range finding and MTD studies provide the initial, indispensable safety data that guides the entire development pathway. These studies are designed to identify dose-limiting toxicities and establish a preliminary safety margin before committing to resource-intensive GxP-compliant programs.

The selection of appropriate analytical methods is fundamental to the success of these early studies. For instance, understanding the tissue-specific expression profile of a vector is a prerequisite for interpreting toxicology data. As research into reporter systems for gene transfer has shown, different reporters can yield varied expression profiles, which directly impacts the assessment of delivery efficiency and potential non-target tissue effects (PMID: 17510373). An informed choice of reporter or analytical method ensures that biodistribution data is accurate and translatable.

Mitigating High-Dose Toxicity Risks

High-dose administration of advanced therapeutics can reveal unexpected safety signals. Systemic delivery of AAV vectors, for example, has been associated with acute liver injury and effects on the liver microvasculature, characterized by transaminitis and thrombocytopenia (PMID: 38327046). This highlights a specific vulnerability at high vector concentrations. Identifying such potential liabilities early in a DRF or MTD study is a primary objective. Our approach incorporates sensitive biomarkers and comprehensive histology to detect subtle signs of organ stress, allowing for proactive risk mitigation and informing the design of safer, more effective constructs.